After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
Joaquín Arribas
Researchers from the Hospital del Mar Research Institute and the VHIO’s Growth Factors Group have demonstrated, in animal models, the…
Engineering T cells directly inside the patient’s body to turn them into CAR-T cells ready to attack tumor cells, using…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
The Breast Cancer Research Foundation (BCRF) is investing $70.3 million—BCRF’s largest annual program in its 31-year history— to fund breast…
Laboratory tests with mice reveal ‘exciting’ new strategy that could transform triple-negative breast cancer into a manageable disease Researchers at…
The Breast Cancer Research Foundation (BCRF) will commit $60.2 million to breast cancer research in 2023-2024, supporting more than 250…
VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC inhibitor Omomyc effectively halts disease progression in metastatic…
Redirection of lymphocytes, via T-cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs), is already approved to treat some hematologic…
